Combination chemotherapy of irinotecan combined with bolus 5-fluorouracil, continuous infusion 5-fluorouracil, and high dose leucovorin every two weeks in recurrent or metastatic colorectal cancer.
- Author:
Jee Hyun KIM
1
;
Do Yeun KIM
;
Se Hoon LEE
;
Sook Ryun PARK
;
Sang Yoon LEE
;
In Sil CHOI
;
Tae You KIM
;
Dae Seog HEO
;
Yung Jue BANG
;
Noe Kyeong KIM
Author Information
1. Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea. heo1013@plaza.snu.ac.kr
- Publication Type:Original Article ; Clinical Trial
- Keywords:
Irinotecan;
Colorectal neoplasm;
Clinical trials;
Phase II
- MeSH:
Aged;
Appointments and Schedules;
Chemotherapy, Adjuvant;
Colorectal Neoplasms*;
Diarrhea;
Drug Therapy;
Drug Therapy, Combination*;
Fluorouracil*;
Humans;
Leucovorin*;
Mortality;
Neutropenia
- From:Korean Journal of Medicine
2003;64(4):452-458
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Irinotecan is an active agent in colorectal cancer, producing 30~40% response rates when combined with 5-fluorouracil and leucovorin in metastatic colorectal cancer as first line therapy, however, the best combination schedules are not determined yet. We investigated the efficacy and toxicity of irinotecan combined with bolus 5-fluorouracil, continuous infusion 5-fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen) in recurrent or metastatic colorectal cancer in Korean patients. METHODS: Twenty-two patients with measurable diseases previously untreated with chemotherapy other than adjuvant chemotherapy for advanced colorectal cancer were enrolled onto this study and received the study drugs between June 2000 and December 2001. Treatment consisted of irinotecan (180 mg/m2 over two hours on day 1) followed by leucovorin (200 mg/m2 over two hours), bolus 5-fluorouracil 400 mg/m2 and continuous infusion of 5-fluorouracil (600 mg/m2 over next 22 hours) on day 1 and 2. Chemotherapy was repeated every two weeks until progressive disease. RESULTS: Of the 20 patients evaluable for response, 8 partial responses were observed with a response rate of 40%. Six additional patients achieved stable disease as their best response, and six progressed. The median time to progression was 5.0 months and median overall survival was 17.3 months. The most frequently observed grade 3~4 toxicities were neutropenia (18%) and diarrhea (4.8%). Two mortalities occurred, though not clearly related to treatment, before the end of chemotherapy. CONCLUSION: Irinotecan combined with LV5FU2 regimen was effective in advanced colorectal cancer with manageable side effects. Caution should be paid to elderly and poor performance patients to prevent treatment related mortality and morbidity.
